Updated Phase I Results of Carboplatin, Pemetrexed and Exemestane in Postmenopausal Women with Metastatic Non-Squamous NSCLC

被引：0
|
作者：
Young, P. [1 ]
Marquez, D. [1 ]
Noor, Z. [1 ]
Callahan, R. [1 ]
Jones, B. [1 ]
Wong, D. [1 ]
Goldman, J. W. [1 ]
Applebaum, S. [1 ]
Rausch, R. [1 ]
Yanes, C. [1 ]
Bueno, S. [1 ]
Garban, N. [1 ]
Elashoff, D. [2 ]
Garon, E. [3 ]
Pietras, R. [4 ]
机构：
[1] Univ Calif Los Angeles, Hematol Oncol, Santa Monica, CA USA
[2] Univ Calif Los Angeles, Med, Los Angeles, CA USA
[3] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA
[4] Univ Calif Los Angeles, David Geffen Sch Med, Med Hematol Oncol, Los Angeles, CA 90095 USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2018年 / 13卷 / 10期
关键词：
estrogen receptor; Exemestane; NSCLC;
D O I：
10.1016/j.jtho.2018.08.661
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1.01-104
引用
收藏
页码：S504 / S504
页数：1
相关论文
共 50 条
  • [41] Maintenance Therapy in advanced non-squamous NSCLC With Pemetrexed a Survival Advantage can be achieved
    不详
    ONKOLOGIE, 2012, 35 (09):
  • [42] Phase I trial of pemetrexed, carboplatin, and sorafenib as first-line treatment in patients with metastatic NSCLC.
    Brandts, C. H.
    Borchard, B.
    Waller, C. F.
    Martens, U. M.
    Mohr, M.
    Young, C.
    Gerss, J.
    Serve, H.
    Berdel, W. E.
    Wiewrodt, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [43] CARBOPLATIN AND PEMETREXED FOR NON-SQUAMOUS NON-SMALL CELL LUNG CANCER - OVERALL SURVIVAL AND TOXICITY
    Andersen, R.
    Mellemgaard, A.
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (06) : S73 - S73
  • [44] Hospitalization and Survival of Medicare Patients Treated With Carboplatin Plus Paclitaxel or Pemetrexed for Metastatic, Non-squamous, Non-Small Cell Lung Cancer
    Brooks, Gabriel A.
    Austin, Andrea M.
    Uno, Hajime
    Dragnev, Konstantin H.
    Tosteson, Anna N. A.
    Schrag, Deborah
    JAMA NETWORK OPEN, 2018, 1 (06)
  • [45] A phase II study of metformin plus pemetrexed and carboplatin in patients with non-squamous non-small cell lung cancer (METALUNG)
    S. Verma
    S. Chitikela
    V. Singh
    S. Khurana
    D. Pushpam
    D. Jain
    S. Kumar
    Y. Gupta
    P. S. Malik
    Medical Oncology, 40
  • [46] Promising targets and current clinical trials in metastatic non-squamous NSCLC
    Zer, Alone
    Leighl, Natasha
    FRONTIERS IN ONCOLOGY, 2014, 4
  • [47] A phase II study of metformin plus pemetrexed and carboplatin in patients with non-squamous non-small cell lung cancer (METALUNG)
    Verma, S.
    Chitikela, S.
    Singh, V.
    Khurana, S.
    Pushpam, D.
    Jain, D.
    Kumar, S.
    Gupta, Y.
    Malik, P. S.
    MEDICAL ONCOLOGY, 2023, 40 (07)
  • [48] Continuous Intravenous Infusion Endostar Combined with Pemetrexed plus Cisplatin in Chinese Treatment-Naive Metastatic Non-Squamous NSCLC
    Chen, L.
    Ji, Q.
    Wang, X.
    Lu, Z.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2075 - S2076
  • [49] Phase I dose-escalation study of oral vinorelbine (VRLO) plus pemetrexed (PEM) in patients (pts) with advanced or metastatic non-squamous non-small-cell lung cancer (NSCLC).
    Isabel Sierra, Marta
    Losa, Raquel
    Tresguerres, Maria
    Gutierrez Restrepo, Eduardo
    Perez, Quionia
    Alvarez, Carlos
    Pablo Berros, Jose
    Villanueva, Noemi
    Manuel Gracia, Jose
    Esteban, Emilio
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [50] Phase II study of pemetrexed and carboplatin plus bevacizumab, followed by maintenance pemetrexed and bevacizumab in Japanese patients with non-squamous non-small cell lung cancer
    Yokoi, Takashi
    Torii, Yoshitaro
    Katashiba, Yuichi
    Sugimoto, Hiroyuki
    Tanijiri, Tsutomu
    Ogata, Makoto
    Inagaki, Noriko
    Kibata, Kayoko
    Hayashi, Mina
    Niki, Maiko
    Shimizu, Toshiki
    Miyara, Takayuki
    Kurata, Takayasu
    Nomura, Shosaku
    ONCOLOGY LETTERS, 2014, 8 (06) : 2453 - 2457
12345